MINNEAPOLIS--(BUSINESS WIRE)--Results of the largest ever Continuous Glucose Monitoring (CGM) study were published online today by the New England Journal of Medicine. The study demonstrated that Personal CGM therapy significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes, validating the growing body of clinical evidence in support of Personal CGM therapy and its ability to substantially improve diabetes management and glucose control. Studies have shown that reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.
